MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, ...

Hercules Pharmaceuticals (Hercules), a national leader in pharmaceutical distribution, today announced that it has been approved as an authorized distributor in the 340B Prime Vendor Program ...

Global Influenza Diagnostics Market OverviewThe global influenza diagnostics market is projected to expand at a CAGR of 5–8% over the next five years. Market growth is fueled by the rising prevalence ...

TURKU, FI / ACCESS Newswire / December 8, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Significant efficacy observed in TP53-mutated patients with a 70% complete remission rate in the ...

Care Market OverviewThe global digital musculoskeletal (MSK) care market is projected to grow at a significant CAGR of 18–20% over the next five years, driven by multiple transformative forces shaping ...

Global Smart Pills Market OverviewThe global smart pills market is projected to grow at a CAGR of 10–12% over the next five years, driven by the increasing prevalence of chronic diseases, rapid ...

Key factors driving this growth include the rising prevalence of cancer, continuous advancements in CAR T-cell technologies, a ...

Global IoT Medical Devices Market OverviewThe global IoT medical devices market is projected to grow at a rate of 25–30% over the next five years, driven by the rising demand for real-time patient ...

All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in NovemberAgreement includes approximately US$ 350 m in cash for Just - ...

MIAMI, FLORIDA / ACCESS Newswire / December 7, 2025 / MSP Recovery, Inc. (NASDAQ:MSPR) (the "Company"), a Medicare, Medicaid, ...

The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have access to controlled substances for legitimate medical use.Today, the evidence shows the opposite: ...

BioInvent International (STO:BINV)46% objective response rate (6 of 13 evaluable patients) and a 92% disease control rate (12 of 13) in relapsed/refractory CTCLImmune activation confirmed by CD8+ T ...